---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-24-000039"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:19:22.342997+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q4 rev $155.1M (+22% YoY); GAAP net loss $187.0M incl $83.4M legal accrual; 2024 guidance $655-670M

## Summary
- Fourth quarter 2023 revenue $155.1M, up 22% YoY; full year revenue $563.9M, up 25%.
- GAAP net loss Q4 $187.0M ($1.58 per share) vs $139.9M ($1.36) prior year, including $83.4M non-recurring legal accrual.
- Clinical test volume 46,400 in Q4 (+29% YoY); full year 172,900 (+39% YoY).
- 2024 revenue guidance $655-670M (16-19% growth); non-GAAP op expense $740-750M; free cash flow -$320 to -$330M.
- Cash and marketable securities $1.2B at year-end; Shield PMA submission under FDA review, expect FDA approval and launch in 2024.

## SEC filing metadata
- accession: 0001576280-24-000039
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000039/0001576280-24-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000039/gh-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-24-000039
- JSON: https://secwatch.observer/filing/0001576280-24-000039.json
- Plain text: https://secwatch.observer/filing/0001576280-24-000039.txt

## Key facts
- Earnings Releases
  Guardant Health, Inc. updated its full year 2024 guidance (initiated).
  - Period: full year 2024
  - Guidance: initiated
  - Result: guidance update
  source text: Expects full year 2024 revenue to be in the range of $655 to $670 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000039/0001576280-24-000039-index.htm
- Earnings Releases
  Guardant Health, Inc. reported the fourth quarter of 2023 results: revenue $155.1 million, net income Net loss was $187.0 million, EPS Net loss per share was $1.58.
  - Period: the fourth quarter of 2023
  - Revenue: $155.1 million
  - Net income: Net loss was $187.0 million
  - EPS: Net loss per share was $1.58
  - Result: reported results
  source text: leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights • Revenue of $155.1 million for the fourth quarter of 2023, an increase of 22% over the fourth quarter of 2022 • Reported 46,400 tests to clinical customers and 9,500 tests to biopharmaceutical customers in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000039/0001576280-24-000039-index.htm
- Earnings Releases
  Guardant Health, Inc. reported the full year ended December 31, 2023 results: revenue $563.9 million. Guidance reaffirmed.
  - Period: the full year ended December 31, 2023
  - Revenue: $563.9 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Revenue was $563.9 million for 2023, a 25% increase from $449.5 million for the corresponding prior year period
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000039/0001576280-24-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.